Evidence-Based Results: GLP-1 therapy is supported by numerous clinical trials, with patients experiencing up to 15% body weight reduction on average
evaluation needed if bleeding is persistent (more than 14 days continuous) or heavy Cycle completely stops (amenorrhea): Multiple possible mechanisms: excessive caloric restriction, body fat percentage dropping below threshold for menstruation (typically under 18% to 20%), hypothalamic suppression, or pregnancy Typical timeline: if related to Zepbound, usually after 12+ weeks and significant weight loss (more than 15% of body weight) What it means: needs evaluation

no LD50 established even at very high doses in rodents No Hormonal Effects: Does not affect testosterone, estrogen, growth hormone, or other hormonal axes Gastric Origin: Derived from a naturally occurring human gastric protein, suggesting good biological compatibility Stability: Unusually stable in gastric acid, supporting oral administration potential Reported Effects: Anecdotal reports of fatigue, nausea in some research subjects TB-500 Safety Profile: (PMID: 20536472) Note: Published safety data is primarily available for Thymosin Beta-4
Comprehensive assessment of the effectiveness of l-carnitine and transresveratrol in rats with diet-induced obesity
These results have generated immense excitement within the medical community
Safety & Contraindications Neither BPC-157 nor TB-500 is FDA-approved for human use